Short Interest in Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) Declines By 10.0%

Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) saw a large decrease in short interest during the month of November. As of November 30th, there was short interest totalling 900 shares, a decrease of 10.0% from the November 15th total of 1,000 shares. Based on an average trading volume of 30,300 shares, the days-to-cover ratio is currently 0.0 days.

Emmaus Life Sciences Trading Up 93.3 %

OTCMKTS EMMA opened at $0.01 on Tuesday. Emmaus Life Sciences has a 12 month low of $0.00 and a 12 month high of $0.13. The company’s 50-day moving average price is $0.03 and its 200-day moving average price is $0.04. The stock has a market cap of $827,064.70, a PE ratio of -0.14 and a beta of 6.20.

Emmaus Life Sciences Company Profile

Emmaus Life Sciences, Inc, a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.